✦ LIBER ✦

A phase 2a study to investigate drug–drug interactions between escalating doses of AT2220 (duvoglustat hydrochloride) and acid alfa-glucosidase in subjects with Pompe disease

✍ Scribed by Kishnani, Priya; Tarnopolsky, Mark; Sivakumar, Kumarswamy; Roberts, Mark; Byrne, Barry; Goker-Alpan, Ozlem; Guter, Karl; Pervaiz, Muhammad Ali; Dasouki, Majed; Mozaffar, Tasheen; Finanger, Erika; Johnson, Franklin; Boudes, Pol

Book ID: 123587141
Publisher: Elsevier Science
Year: 2013
Tongue: English
Weight: 61 KB
Volume: 108
Category: Article
ISSN: 1096-7192
DOI: 10.1016/j.ymgme.2012.11.131

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

T.P.46 A novel phase 2a study design to

T.P.46 A novel phase 2a study design to investigate drug-drug interactions between escalating doses of AT2220 (duvoglustat hydrochloride) and acid alpha-glucosidase in subjects with Pompe disease

✍ Kishnani, P.; Tarnopolsky, M.; Sivakumar, K.; Byrne, B.; Goker-Alpan, O.; Guter, 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 48 KB

T.P.45 An ongoing phase 2a study to inve

T.P.45 An ongoing phase 2a study to investigate drug–drug interactions between escalating doses of AT2220 (duvoglustat hydrochloride) and acid alpha glucosidase in subjects with Pompe disease – Preliminary results

✍ Kishnani, P.; Tarnopolsky, M.; Sivakumar, K.; Byrne, B.; Goker-Alpan, O.; Guter, 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 49 KB